Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest advance in AML treatment due to significant overall survival improvements, ...
Please provide your email address to receive an email when new articles are posted on . The addition of venetoclax to azacitidine benefited untreated patients with isocitrate dehydrogenase mutations ...
Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...
Voranigo is rapidly adopted for IDH-mutated glioma, addressing unmet needs and shifting towards earlier intervention. Retrospective analysis identified 520 patients treated with Voranigo, with 41% ...
New York, USA, July 29, 2024 (GLOBE NEWSWIRE) -- IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight DelveInsight’s IDH Inhibitor Market Insights ...
Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...
Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma. Background: IDH mutant astrocytomas express high levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results